EC Number | Application | Comment | Organism |
---|---|---|---|
1.8.1.9 | medicine | TR1 acts largely as a pro-cancer protein and it is a primary target in cancer therapy | Mus musculus |
1.8.1.9 | medicine | TR1 acts largely as a pro-cancer protein and it is a primary target in cancer therapy | Homo sapiens |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
1.8.1.9 | selenium | selenoprotein | Mus musculus | |
1.8.1.9 | selenium | selenoprotein | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.8.1.9 | Homo sapiens | Q16881 | - |
- |
1.8.1.9 | Mus musculus | Q9JMH6 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.8.1.9 | A-549 cell | human lung non-small cell carcinoma | Homo sapiens | - |
1.8.1.9 | ACHN cell | human kidney renal cell carcinoma | Homo sapiens | - |
1.8.1.9 | HCT-116 cell | human colon cell adenocarcinoma | Homo sapiens | - |
1.8.1.9 | LLC1 cell | - |
Mus musculus | - |
1.8.1.9 | NIH-3T3 cell | TR1 is uniquely overexpressed in cancer cells and its knockdown in a mouse cancer cell line driven by oncogenic k-ras results in orphological changes characteristic of parental (normal) cells, without significant effect on cell growth under normal growth conditions. When grown in serum-deficient medium, TR1 deficient cancer cells lose self-sufficiency of growth, manifest a defective progression in their S phase and a decreased expression of DNA polymerase alpha | Mus musculus | - |
1.8.1.9 | SNB-19 cell | human cell glioblastoma | Homo sapiens | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.8.1.9 | thioredoxin reductase 1 | - |
Mus musculus |
1.8.1.9 | thioredoxin reductase 1 | - |
Homo sapiens |
1.8.1.9 | TR1 | - |
Mus musculus |
1.8.1.9 | TR1 | - |
Homo sapiens |